(Q54581202)

1 June 2018

title

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. (English)

1 reference

1 June 2018

0 references

Jordan S Fridman

1

1 reference

1 June 2018

Peggy A Scherle

2

1 reference

1 June 2018

Robert Collins

3

1 reference

1 June 2018

Timothy Burn

4

1 reference

1 June 2018

Claire L Neilan

5

1 reference

1 June 2018

Denise Hertel

6

1 reference

1 June 2018

Nancy Contel

7

1 reference

1 June 2018

Patrick Haley

8

1 reference

1 June 2018

Beth Thomas

9

1 reference

1 June 2018

Jack Shi

10

1 reference

1 June 2018

Paul Collier

11

1 reference

1 June 2018

James D Rodgers

12

1 reference

1 June 2018

Stacey Shepard

13

1 reference

1 June 2018

Brian Metcalf

14

1 reference

1 June 2018

Gregory Hollis

15

1 reference

1 June 2018

Robert C Newton

16

1 reference

1 June 2018

Swamy Yeleswaram

17

1 reference

1 June 2018

Steven M Friedman

18

1 reference

1 June 2018

Kris Vaddi

19

1 reference

1 June 2018

language of work or name

English

0 references

publication date

16 June 2011

1 reference

1 June 2018

Journal of Investigative Dermatology

published in

1 reference

1 June 2018

volume

131

1 reference

1 June 2018

issue

9

1 reference

1 June 2018

page(s)

1838-1844

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/jid.2011.140

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Th17 cells: a new fate for differentiating helper T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The IL-23/Th17 axis in the immunopathogenesis of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Janus kinases in immune cell signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Psoriasis: emerging therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Cloning and characterization of a functional promoter of the human SOCS-3 gene

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The psychosocial and occupational impact of chronic skin disease

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The Janus protein tyrosine kinases in hematopoietic cytokine signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Thymic stromal lymphopoietin: master switch for allergic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The cytokine network in psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Cracking the cytokine code in psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The cytokine and chemokine network in psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Cytokine signaling modules in inflammatory responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

A new modality for immunosuppression: targeting the JAK/STAT pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

New aspects of the mechanism of corticosteroid–induced dermal atrophy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Jak2 is essential for signaling through a variety of cytokine receptors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Therapeutic targeting of Janus kinases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

https://api.crossref.org/works/10.1038%2FJID.2011.140

1 reference

7 January 2021

Regulation of JAK-STAT signalling in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.140

7 January 2021

Identifiers

DOI

10.1038/JID.2011.140

1 reference

1 June 2018

Dimensions Publication ID

1052293821

0 references

1 reference

1 June 2018